Skip to main content
SpringerLink
Log in

Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease

  • Chapter
  • First Online:
Evidence-Based Cardiology Consult

Abstract

Hypertension is an independent risk factor for cardiovascular disease events. There is a continuous relationship between both systolic and diastolic blood pressure levels and the chance of a heart attack or heart failure beginning at a blood pressure of 115/75 mmHg (Lewington et al., Lancet 360:1903–1913, 2002). The heart, central nervous system, kidneys, and peripheral arterial system are the major target organs that are susceptible to hypertensive disease. The most important treatment goal, however, is blood pressure control, and the choice of agent used to reach treatment goals may be less important. Although clinical trial data is lacking, a treatment target of 130/80 mmHg as recommended by the AHA is a reasonable target until further studies better define the optimal blood pressure in patients with established heart disease. Care may be needed in the elderly and patients with advanced diabetes and severe CAD to avoid treating too low blood pressure with the possibility of increasing adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.

    Article  PubMed  Google Scholar 

  2. Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich). 2005;7(9):505–12.

    Article  Google Scholar 

  3. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152(7):1490–500.

    Article  PubMed  CAS  Google Scholar 

  4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.

    Google Scholar 

  5. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.

    Article  PubMed  CAS  Google Scholar 

  6. McMahan CA, Gidding SS, Fayad ZA, et al. Risk scores predict atherosclerotic lesions in young people. Arch Intern Med. 2005;165(8):883–90.

    Article  PubMed  Google Scholar 

  7. Boon D, Piek JJ, van Montfrans GA. Silent ischaemia and hypertension. J Hypertens. 2000;18(10):1355–64.

    Article  PubMed  CAS  Google Scholar 

  8. Njolstad I, Arnesen E. Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. Arch Intern Med. 1998;158(12):1326–32.

    Article  PubMed  CAS  Google Scholar 

  9. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.

    Article  PubMed  CAS  Google Scholar 

  10. Kalaitzidis RG, Bakris GL. Pros and cons of aggressive blood pressure lowering in patient with type 2 diabetes. Curr Vasc Pharmacol. 2012;10:156–61.

    Article  PubMed  CAS  Google Scholar 

  11. Upadhyay A, Early A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.

    Article  PubMed  Google Scholar 

  12. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761–88.

    Article  PubMed  Google Scholar 

  13. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003;290:2805–16.

    Article  PubMed  CAS  Google Scholar 

  14. Cooper-DeHof RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.

    Article  Google Scholar 

  15. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25.

    Article  PubMed  CAS  Google Scholar 

  16. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med. 2002;136(6):438–48.

    Article  PubMed  Google Scholar 

  17. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Google Scholar 

  18. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255–64.

    Google Scholar 

  19. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.

    Article  PubMed  CAS  Google Scholar 

  20. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ. 2007;334(7600):946–9.

    Article  PubMed  CAS  Google Scholar 

  21. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a mulitcentre randomised controlled trial. Lancet. 2005;366:895–906.

    Article  PubMed  Google Scholar 

  22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.

    Article  PubMed  CAS  Google Scholar 

  23. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–8.

    Article  PubMed  CAS  Google Scholar 

  24. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 1987;60(17):85I–93.

    Article  PubMed  CAS  Google Scholar 

  25. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;60(7):560–5.

    Article  PubMed  CAS  Google Scholar 

  26. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561–6.

    Article  PubMed  CAS  Google Scholar 

  27. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104(17):2039–44.

    Article  PubMed  CAS  Google Scholar 

  28. Beache GM, Herzka DA, Boxerman JL, et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation. 2001;104(11):1214–7.

    Article  PubMed  CAS  Google Scholar 

  29. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

    Article  PubMed  CAS  Google Scholar 

  30. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81(3):815–20.

    Article  PubMed  CAS  Google Scholar 

  31. Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38(7):1829–35.

    Article  PubMed  CAS  Google Scholar 

  32. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41–6.

    Article  PubMed  Google Scholar 

  33. Franz IW, Tonnesmann U, Muller JF. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens. 1998;11(6 Pt 1):631–9.

    Article  PubMed  CAS  Google Scholar 

  34. Aljaroudi W, Alraies MC, Halley C, et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation. 2012;125(6):782–8.

    Article  PubMed  Google Scholar 

  35. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.

    Article  PubMed  CAS  Google Scholar 

  36. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292(19):2350–6.

    Article  PubMed  CAS  Google Scholar 

  37. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16(11 Pt 1):895–9.

    Article  PubMed  Google Scholar 

  38. Miller AB, Reichek N, St John SM, et al. Importance of blood pressure control in left ventricular mass regression. J Am Soc Hypertens. 2010;4(6):302–10.

    Article  PubMed  Google Scholar 

  39. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260–9.

    Article  PubMed  CAS  Google Scholar 

  40. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  PubMed  CAS  Google Scholar 

  41. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351(11):1097–105.

    Article  PubMed  CAS  Google Scholar 

  42. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–4.

    Article  PubMed  CAS  Google Scholar 

  43. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–45.

    Article  PubMed  CAS  Google Scholar 

  44. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.

    Article  PubMed  CAS  Google Scholar 

  45. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67.

    Article  PubMed  CAS  Google Scholar 

  46. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    Article  PubMed  CAS  Google Scholar 

  47. Gonzaga CC, Calhoun DA. 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? Pol Arch Med Wewn. 2008;118:196–7.

    Google Scholar 

  48. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens. 2011;13:146–54.

    Article  Google Scholar 

  49. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1998 to 2008. Circulation. 2011;124:1046–58.

    Article  PubMed  Google Scholar 

  50. Bakris GL, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152–8.

    Article  PubMed  Google Scholar 

  51. Kandzari DE, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol. 2012;35:528–35.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine/Cardiology, University of Chicago, 5841 S. Maryland Ave, MC 6080, Chicago, IL, 60305, USA

    Matthew Sorrentino MD, FACC, FASH

  2. Department of Medicine, ASH Hypertension Center, The University of Chicago Medicine, 5841 S. Maryland Ave, MC 1027, Chicago, IL, 46321, USA

    George L. Bakris MD

Authors
  1. Matthew Sorrentino MD, FACC, FASH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George L. Bakris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew Sorrentino MD, FACC, FASH .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Department of Medicine,, Stony Brook University, School of Medicine,, Stony Brook, USA

    Kathleen Stergiopoulos

  2. Division of Cardiology, Stony Brook University, Stony Brook, New York, USA

    David L. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Sorrentino, M., Bakris, G.L. (2014). Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease. In: Stergiopoulos, K., Brown, D. (eds) Evidence-Based Cardiology Consult. Springer, London. https://doi.org/10.1007/978-1-4471-4441-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4441-0_4

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4440-3

  • Online ISBN: 978-1-4471-4441-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation